Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

AtriCure stock

ATRC
US04963C2098
A0ES9W

Price

28.04
Today +/-
-0.13
Today %
-0.50 %
P

AtriCure stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AtriCure stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AtriCure stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AtriCure stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AtriCure's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AtriCure Stock Price History

DateAtriCure Price
9/30/202428.04 undefined
9/27/202428.18 undefined
9/26/202428.42 undefined
9/25/202428.58 undefined
9/24/202429.50 undefined
9/23/202429.05 undefined
9/20/202429.02 undefined
9/19/202428.81 undefined
9/18/202427.99 undefined
9/17/202428.07 undefined
9/16/202427.30 undefined
9/13/202428.21 undefined
9/12/202427.71 undefined
9/11/202426.90 undefined
9/10/202426.87 undefined
9/9/202426.25 undefined
9/6/202426.24 undefined
9/5/202426.14 undefined
9/4/202426.21 undefined
9/3/202425.94 undefined

AtriCure Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AtriCure, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AtriCure from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AtriCure’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AtriCure. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AtriCure’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AtriCure’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AtriCure’s growth potential.

AtriCure Revenue, EBIT and net profit per share

DateAtriCure RevenueAtriCure EBITAtriCure Net Income
2027e750.01 M undefined-22.54 M undefined-20.86 M undefined
2026e596.65 M undefined-17.88 M undefined-21.98 M undefined
2025e529.98 M undefined-24.24 M undefined-30.97 M undefined
2024e467.27 M undefined-31.51 M undefined-39.18 M undefined
2023399.25 M undefined-26.68 M undefined-30.44 M undefined
2022330.4 M undefined-42.7 M undefined-46.5 M undefined
2021274.3 M undefined137.5 M undefined50.2 M undefined
2020206.5 M undefined-40.4 M undefined-48.2 M undefined
2019230.8 M undefined-29.1 M undefined-35.2 M undefined
2018201.6 M undefined-17.1 M undefined-21.1 M undefined
2017174.7 M undefined-25 M undefined-26.9 M undefined
2016155.1 M undefined-31.1 M undefined-33.3 M undefined
2015129.8 M undefined-26.7 M undefined-27.2 M undefined
2014107.5 M undefined-16.4 M undefined-16.2 M undefined
201381.9 M undefined-10.9 M undefined-11.5 M undefined
201270.2 M undefined-7.2 M undefined-7.5 M undefined
201164.4 M undefined-4.7 M undefined-5.5 M undefined
201059 M undefined-3.2 M undefined-3.8 M undefined
200954.5 M undefined-4.7 M undefined-16.5 M undefined
200855.3 M undefined-11 M undefined-10.2 M undefined
200748.3 M undefined-12.6 M undefined-11.3 M undefined
200638.2 M undefined-14.8 M undefined-13.7 M undefined
200531 M undefined-10.9 M undefined-12.7 M undefined
200419.2 M undefined-5.7 M undefined-9.5 M undefined

AtriCure Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
1919313848555459647081107129155174201230206274330399467529596750
-800.00111.1163.1622.5826.3214.58-1.829.268.479.3815.7132.1020.5620.1612.2615.5214.43-10.4333.0120.4420.9117.0413.2812.6725.84
100.0077.7873.6870.9778.9579.1776.3675.9376.2773.4471.4372.8470.0971.3271.6172.4173.1373.9172.3374.8274.2475.19----
171422303842414547505975921111261471701492052453000000
-5-3-5-10-14-12-11-4-3-4-7-10-16-26-31-25-17-29-40137-42-26-31-24-17-22
-500.00-33.33-26.32-32.26-36.84-25.00-20.00-7.41-5.08-6.25-10.00-12.35-14.95-20.16-20.00-14.37-8.46-12.61-19.4250.00-12.73-6.52-6.64-4.54-2.85-2.93
-9-7-9-12-13-11-10-16-3-5-7-11-16-27-33-26-21-35-4850-46-30-39-30-21-20
--22.2228.5733.338.33-15.38-9.0960.00-81.2566.6740.0057.1445.4568.7522.22-21.21-19.2366.6737.14-204.17-192.00-34.7830.00-23.08-30.00-4.76
12.112.112.112.112.113.414.214.615.115.716.220.426.428.131.632.434.137.642.14645.746.310000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The AtriCure Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AtriCure is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
10.45.233.819.52011.415.712.614.21226.259.634.64434.5124.481.8244.2119.1121.1137.29
1.63.54.96.67.26.57.29.59.59.913.717.619.421.123.125.22823.13342.752.5
000000000000000000000
0.61.12.13.45.36.44.95.76.65.710.214.317.717.722.522.529.4353945.967.9
0.20.10.81.21.41.83.52.90.90.92.423.132.32.63.94.355.58.56
12.89.941.630.733.926.131.330.731.228.552.593.574.885.882.4174.7143.1306.6196.1215.2266.25
1.92.43.43.64.53.732.72.43.45.611.631.33028.727.136.730.236.242.646.76
00000000007.98.97.730012.714.2104.351.50
000000000000000000000
0010.80.90.60.30.10010.38.953.852.150.849.3129.9128.24339.363.99
003.83.86.86.8000035.435.4105.3105.3105.3105.3234.8234.8234.8234.8234.78
00.40.20.20.16.20.30.30.30.40.20.20.30.30.70.50.70.4122.16
1.92.88.48.412.317.33.63.12.73.859.465198.4190.7185.5182.2414.8407.8419.3370.2347.69
14.712.75039.146.243.434.933.833.932.3111.9158.5273.2276.5267.9356.9557.9714.4615.4585.4613.93
                                         
32.836.80000000000000000000.05
1.23.386.186.6103.5106.6110.9114.4118.9123.2194.9271.3352.9367.9387496.5529.7742.4764.8787.4824.17
-20.1-29.6-42.3-56.1-67.3-77.5-94-97.8-103.2-110.8-122.2-138.4-165.6-199-225.9-247-282.2-330.4-280.2-326.6-357.06
0-1,000-6001000-1001001000100-100-300-600-4000-200-300300-100-400-193
00000000000-1000000100100-900-3,700-800
13.99.543.230.636.2291716.715.712.572.6132.5186.7168.5161.1249.3247.3412.4483.6456.7466.17
0.30.71.23.64.75.23.64.55.35.18.67.612.710.712.49.714.912.718.619.927.35
0.62.64.13.73.82.966.345.116.11417.515.218.32532.627.735.534.246.13
0000000002241.431.25.61.77.91.500
000000000000000000000
000.40.40.802.22.21.500000000.80.80.94.31.09
0.93.35.77.79.38.111.81310.812.226.725.631.628.931.940.35049.156.558.474.57
001.10.70.362.70.74.96.44.40.113.737.236.947.771.464.469.86668.65
000000000000000000000
0000.10.30.13.43.32.51.38.20.141.141.937.819.4189.2188.65.34.34.54
001.10.80.66.16.147.47.712.60.254.879.174.767.1260.625375.170.373.2
0.93.36.88.59.914.217.91718.219.939.325.886.4108106.6107.4310.6302.1131.6128.7147.76
14.812.85039.146.143.234.933.733.932.4111.9158.3273.1276.5267.7356.7557.9714.5615.2585.4613.93
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AtriCure provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AtriCure's financial health and stability.

Assets

AtriCure's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AtriCure must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AtriCure after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AtriCure's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-9-7-9-12-13-11-10-16-3-5-7-11-16-27-33-26-21-35-4850-46-30
0001122221124699899101114
0000000000000000000000
0-100-1-1-10-1-101-112-5-21-4-6-4-18-18
33431151856768192525233248-416074
0000000000000012334446
0000000000000000000000
-5-3-3-7-12-8-500-1-1-5-21-7-15-8-4-15-19-13-224
-1-1-1-1-1-3-1-1-1-1-2-2-5-13-7-6-6-12-5-9-16-41
-1-1-1-140-8-1-2-32-2-14-30-10-123-85-2-156234421
000-121-500-140-11-252-410-7910-150336063
0000000000000000000000
30010050-231-2-21024-115190000
1700430150002129694469132031267
20004401550-14226651327210014189-7-70
---------------1.00-2.00-6.00-8.00-13.00-19.00-12.00-6.00
0000000000000000000000
13-5-522-12-1-1-2-45-2713-40-210-31311426
-7.16-5.05-5.31-9.57-14.15-11.16-7.46-0.94-1.84-3.51-4.93-8.08-27.11-21.29-22.81-15.32-10.38-27.99-25.13-23.53-39.02-37.51
0000000000000000000000

AtriCure stock margins

The AtriCure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AtriCure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AtriCure.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AtriCure's sales revenue. A higher gross margin percentage indicates that the AtriCure retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AtriCure's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AtriCure's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AtriCure's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AtriCure. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AtriCure's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AtriCure Margin History

AtriCure Gross marginAtriCure Profit marginAtriCure EBIT marginAtriCure Profit margin
2027e75.23 %-3.01 %-2.78 %
2026e75.23 %-3 %-3.68 %
2025e75.23 %-4.57 %-5.84 %
2024e75.23 %-6.74 %-8.39 %
202375.23 %-6.68 %-7.62 %
202274.42 %-12.92 %-14.07 %
202175.06 %50.13 %18.3 %
202072.3 %-19.56 %-23.34 %
201973.79 %-12.61 %-15.25 %
201872.97 %-8.48 %-10.47 %
201772.24 %-14.31 %-15.4 %
201671.63 %-20.05 %-21.47 %
201571.57 %-20.57 %-20.96 %
201470.51 %-15.26 %-15.07 %
201372.77 %-13.31 %-14.04 %
201271.23 %-10.26 %-10.68 %
201172.98 %-7.3 %-8.54 %
201076.95 %-5.42 %-6.44 %
200976.7 %-8.62 %-30.28 %
200875.95 %-19.89 %-18.44 %
200779.09 %-26.09 %-23.4 %
200680.1 %-38.74 %-35.86 %
200573.87 %-35.16 %-40.97 %
200472.92 %-29.69 %-49.48 %

AtriCure Stock Sales Revenue, EBIT, Earnings per Share

The AtriCure earnings per share therefore indicates how much revenue AtriCure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AtriCure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AtriCure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AtriCure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AtriCure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AtriCure Revenue, EBIT and net profit per share

DateAtriCure Sales per ShareAtriCure EBIT per shareAtriCure Earnings per Share
2027e15.4 undefined0 undefined-0.43 undefined
2026e12.25 undefined0 undefined-0.45 undefined
2025e10.88 undefined0 undefined-0.64 undefined
2024e9.59 undefined0 undefined-0.8 undefined
20238.62 undefined-0.58 undefined-0.66 undefined
20227.23 undefined-0.93 undefined-1.02 undefined
20215.96 undefined2.99 undefined1.09 undefined
20204.9 undefined-0.96 undefined-1.14 undefined
20196.14 undefined-0.77 undefined-0.94 undefined
20185.91 undefined-0.5 undefined-0.62 undefined
20175.39 undefined-0.77 undefined-0.83 undefined
20164.91 undefined-0.98 undefined-1.05 undefined
20154.62 undefined-0.95 undefined-0.97 undefined
20144.07 undefined-0.62 undefined-0.61 undefined
20134.01 undefined-0.53 undefined-0.56 undefined
20124.33 undefined-0.44 undefined-0.46 undefined
20114.1 undefined-0.3 undefined-0.35 undefined
20103.91 undefined-0.21 undefined-0.25 undefined
20093.73 undefined-0.32 undefined-1.13 undefined
20083.89 undefined-0.77 undefined-0.72 undefined
20073.6 undefined-0.94 undefined-0.84 undefined
20063.16 undefined-1.22 undefined-1.13 undefined
20052.56 undefined-0.9 undefined-1.05 undefined
20041.59 undefined-0.47 undefined-0.79 undefined

AtriCure business model

AtriCure Inc is a medical technology company that specializes in the development of innovative products and therapies for the treatment of cardiac arrhythmias. It was founded in 2000 and is headquartered in Mason, Ohio, USA. The company offers a wide range of products and therapies, including the isolation of pulmonary veins, catheter technology, radiofrequency ablation, and innovative solutions for the treatment of heart valve diseases and other structural heart problems. AtriCure is one of the most popular companies on Eulerpool.com.

AtriCure Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AtriCure Revenue by Segment

Segmente202320222021202020192018201720162015
Appendage Management---12.35 M USD11.48 M USD----
Shipping and Handling1.86 M USD1.5 M USD-------
Open heart---18.66 M USD24.95 M USD-20.72 M USD20.19 M USD16.29 M USD
Ablation and Atriclip------35.98 M USD32.24 M USD27.12 M USD
Minimally invasive---6.17 M USD8.35 M USD-8.01 M USD8.07 M USD7.96 M USD
Atriclip------7.25 M USD3.99 M USD2.87 M USD
Shipping And Handling---1.19 M USD1.49 M USD1.24 M USD---
Shipping and Handling--1.35 M USD------
Valve------353,000 USD484,000 USD424,000 USD
Ablation And Appendage Management---37.18 M USD44.77 M USD----
Total ablation40.17 M USD33.35 M USD-------
Appendage management25.54 M USD19.83 M USD-------
Valve---108,000 USD208,000 USD----
Total ablation and appendage management--45.15 M USD------
Open ablation--23.21 M USD------
Appendage management--15.53 M USD------
Minimally invasive ablation--6.41 M USD------
Valve tools--49,000 USD------

AtriCure Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

AtriCure Revenue by Segment

DateArtiClipAsiaAsia-PacificAtriclipEuropeInternationalMinimally invasiveMinimally InvasiveNon UsOpen heartOpen-heartOther internationalOther InternationalTotal internationalTotal InternationalU [S]United States
2023--24.53 M USD-38.47 M USD-------2.71 M USD-65.7 M USD-333.54 M USD
2022-20.73 M USD--30.43 M USD-------2.02 M USD-53.18 M USD-277.2 M USD
2021-16.08 M USD--27.93 M USD------1.19 M USD-45.2 M USD--229.13 M USD
2020-13.12 M USD--23.22 M USD---37.29 M USD---952,000 USD--169.24 M USD-
2019-15.98 M USD--27.93 M USD---44.98 M USD---1.07 M USD--185.83 M USD-
2017-13.62 M USD--21.9 M USD---36.33 M USD---812,000 USD--138.39 M USD-
2016-12.22 M USD--19.77 M USD---32.72 M USD---729,000 USD--122.39 M USD-
2015-9.51 M USD--17.18 M USD---27.54 M USD---853,000 USD--102.21 M USD-
2014-8.55 M USD--18.16 M USD-------536,000 USD---80.2 M USD
2013-7.67 M USD-10.82 M USD11.38 M USD-13.65 M USD--37.84 M USD--529,000 USD---62.31 M USD
20127 M USD----17.63 M USD-12.73 M USD--32.88 M USD-----52.62 M USD

AtriCure SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

AtriCure Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AtriCure historical P/E ratio, EBIT multiple, and P/S ratio

AtriCure shares outstanding

The number of shares was AtriCure in 2023 — This indicates how many shares 46.309 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AtriCure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AtriCure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AtriCure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AtriCure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for AtriCure.

AtriCure latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.17 -0.17  (0.82 %)2024 Q2
3/31/2024-0.23 -0.28  (-20.17 %)2024 Q1
12/31/2023-0.23 -0.21  (10.29 %)2023 Q4
9/30/2023-0.32 -0.2  (37.05 %)2023 Q3
6/30/2023-0.3 -0.11  (63.49 %)2023 Q2
3/31/2023-0.35 -0.23  (33.43 %)2023 Q1
12/31/2022-0.18 -0.09  (49.78 %)2022 Q4
9/30/2022-0.26 -0.27  (-4.69 %)2022 Q3
6/30/2022-0.3 -0.32  (-7.13 %)2022 Q2
3/31/2022-0.33 -0.33  (-1.2 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the AtriCure stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

40

👫 Social

99

🏛️ Governance

78

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AtriCure shareholders

%
Name
Stocks
Change
Date
9.76376 % The Vanguard Group, Inc.4,754,9498,97812/31/2023
7.26612 % BlackRock Institutional Trust Company, N.A.3,538,602249,65512/31/2023
6.96927 % AllianceBernstein L.P.3,394,036166,82712/31/2023
4.32319 % Champlain Investment Partners, LLC2,105,395253,85512/31/2023
2.97685 % Macquarie Investment Management1,449,726-8,77512/31/2023
2.77093 % First Light Asset Management, LLC1,349,443-139,96412/31/2023
2.72989 % Wellington Management Company, LLP1,329,45795,82412/31/2023
2.47313 % State Street Global Advisors (US)1,204,41556,89612/31/2023
2.36973 % Fred Alger Management, LLC1,154,058-281,75612/31/2023
2.14541 % Invesco Advisers, Inc.1,044,813133,11912/31/2023
1
2
3
4
5
...
10

AtriCure Executives and Management Board

Mr. Michael Carrel52
AtriCure President, Chief Executive Officer, Director (since 2012)
Compensation 8.35 M
Mr. Douglas Seith57
AtriCure Chief Operating Officer
Compensation 3.09 M
Ms. Angela Wirick45
AtriCure Chief Financial Officer
Compensation 2.23 M
Ms. Deborah Yount57
AtriCure Chief Human Resource Officer
Compensation 1.92 M
Mr. Justin Noznesky45
AtriCure Chief Marketing and Strategy Officer
Compensation 1.78 M
1
2
3
4

Most common questions regarding AtriCure

What values and corporate philosophy does AtriCure represent?

AtriCure Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company focuses on delivering groundbreaking solutions for the treatment of atrial fibrillation and other cardiac conditions. AtriCure Inc consistently strives to improve patient outcomes and enhance the quality of life through their innovative medical technologies. The company's commitment to research, development, and continuous improvement enables them to provide cutting-edge solutions that address the evolving needs of patients and healthcare providers. AtriCure Inc's dedication to excellence and patient care sets them apart in the medical device industry.

In which countries and regions is AtriCure primarily present?

AtriCure Inc is primarily present in various countries and regions across the world. The company has a global presence with a focus on North America, Europe, and Asia. AtriCure operates in the United States, where its headquarters are based, and serves customers across the country. It also has a significant presence in European markets, including countries like Germany, France, the United Kingdom, and Italy. Additionally, AtriCure has been expanding its reach in Asia, including markets such as China, Japan, and South Korea. With its widespread presence, AtriCure Inc caters to a diverse range of customers globally.

What significant milestones has the company AtriCure achieved?

AtriCure Inc, a leading medical device company, has achieved several significant milestones. Notably, the company received approval from the U.S. FDA for its AtriClip® System, a revolutionary device that aids in the prevention of stroke during open-heart surgeries. Additionally, AtriCure Inc has successfully expanded its international presence by obtaining regulatory approvals in Europe, Canada, and other countries for the AtriCure® EPi-Sense® System and other innovative products. Moreover, the company has witnessed considerable growth through strategic acquisitions, such as the purchase of SentreHEART, further enhancing its portfolio of advanced cardiac surgical solutions. These milestones highlight AtriCure Inc's commitment to pioneering advancements in surgical technologies to improve patient outcomes.

What is the history and background of the company AtriCure?

AtriCure Inc is a leading medical device company specializing in surgical ablation systems for the treatment of atrial fibrillation and other cardiac arrhythmias. Founded in 2000, AtriCure has been dedicated to advancing innovative technologies and techniques to deliver optimal patient outcomes. With a strong focus on research and development, the company has constantly evolved to provide state-of-the-art solutions for cardiac surgeons and patients. AtriCure's commitment to excellence has earned it a reputation as a trusted leader in the industry. Today, it continues to revolutionize the field of cardiac ablation with its comprehensive portfolio of products and a relentless pursuit of technological advancements.

Who are the main competitors of AtriCure in the market?

The main competitors of AtriCure Inc in the market include Medtronic plc, Boston Scientific Corporation, and Johnson & Johnson.

In which industries is AtriCure primarily active?

AtriCure Inc is primarily active in the healthcare and medical device industries.

What is the business model of AtriCure?

AtriCure Inc is a medical device company specializing in the development and manufacturing of solutions for the treatment of atrial fibrillation and other cardiac disorders. The company's business model primarily revolves around the research, development, production, and commercialization of innovative technologies and surgical devices. By offering advanced cardiac ablation systems, surgical instruments, and related tools, AtriCure Inc aims to provide healthcare professionals with effective solutions for improving patient outcomes in the field of cardiac surgery. As a leading player in the medical device industry, AtriCure Inc embraces a customer-centric approach, focusing on delivering high-quality products and comprehensive support to healthcare providers globally.

What is the P/E ratio of AtriCure 2024?

The AtriCure P/E ratio is -33.14.

What is the P/S ratio of AtriCure 2024?

The AtriCure P/S ratio is 2.78.

What is the AlleAktien quality score of AtriCure?

The AlleAktien quality score for AtriCure is 5/10.

What is the revenue of AtriCure 2024?

The expected AtriCure revenue is 467.27 M USD.

How high is the profit of AtriCure 2024?

The expected AtriCure profit is -39.18 M USD.

What is the business model of AtriCure

AtriCure Inc. is a medical company specializing in the development and sale of cardiology devices. The company offers a wide range of products that can be used for the treatment of heart diseases. The company is divided into three main segments: cardiology, surgery, and pacing. In the cardiology segment, AtriCure offers devices that can be used to restore normal heart rhythms. These devices are commonly used in patients with atrial fibrillation or other cardiac arrhythmias. The surgical segment of AtriCure focuses on the development of devices that can be used in heart surgeries. This includes instruments for tissue removal and devices to support the heart-lung circulation during the operation. The third segment of AtriCure is the pacing segment. Here, the company sells devices that can be used to regulate the heartbeat. They are typically used in patients with cardiac arrhythmias. One of AtriCure's most well-known products is the bipolar cutting and coagulation device. This device is commonly used in cardiac surgeries and allows surgeons to remove tissue quickly and precisely. Another product from AtriCure is the AtriClip system. This is a clip system that is used during heart surgery to close off the left atrium. This can help reduce the risk of atrial fibrillation after the operation. Overall, AtriCure has developed a wide range of medical devices tailored to the needs of cardiology and surgical patients. The company's products are known for their high quality and reliability. The company is constantly striving to develop new, innovative products that have the potential to improve the surgical treatment of heart diseases. An important part of AtriCure's business model is collaboration with other companies and institutions. The company works closely with clinicians, scientists, and companies in the medical industry to develop and test innovative products. To drive the company's growth, AtriCure has made a number of strategic acquisitions. For example, in 2019, the company acquired SentreHeart, which has developed an innovative procedure for the treatment of atrial fibrillation. Overall, AtriCure's business model is focused on continuous improvement and innovation. The company aims to develop high-quality products that can save lives and improve the treatment of heart diseases. AtriCure is continually working to build partnerships and drive the growth of the company to improve patient care in the cardiology community.

What is the AtriCure dividend?

AtriCure pays a dividend of 0 USD distributed over payouts per year.

How often does AtriCure pay dividends?

The dividend cannot currently be calculated for AtriCure or the company does not pay out a dividend.

What is the AtriCure ISIN?

The ISIN of AtriCure is US04963C2098.

What is the AtriCure WKN?

The WKN of AtriCure is A0ES9W.

What is the AtriCure ticker?

The ticker of AtriCure is ATRC.

How much dividend does AtriCure pay?

Over the past 12 months, AtriCure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AtriCure is expected to pay a dividend of 0 USD.

What is the dividend yield of AtriCure?

The current dividend yield of AtriCure is .

When does AtriCure pay dividends?

AtriCure pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AtriCure?

AtriCure paid dividends every year for the past 0 years.

What is the dividend of AtriCure?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AtriCure located?

AtriCure is assigned to the 'Health' sector.

Wann musste ich die Aktien von AtriCure kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AtriCure from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did AtriCure pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of AtriCure in the year 2023?

In the year 2023, AtriCure distributed 0 USD as dividends.

In which currency does AtriCure pay out the dividend?

The dividends of AtriCure are distributed in USD.

All fundamentals about AtriCure

Our stock analysis for AtriCure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AtriCure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.